TY - JOUR
T1 - Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3)
AU - Kaniskan, H. Ümit
AU - Eram, Mohammad S.
AU - Zhao, Kehao
AU - Szewczyk, Magdalena M.
AU - Yang, Xiaobao
AU - Schmidt, Keith
AU - Luo, Xiao
AU - Xiao, Sean
AU - Dai, Miao
AU - He, Feng
AU - Zang, Irene
AU - Lin, Ying
AU - Li, Fengling
AU - Dobrovetsky, Elena
AU - Smil, David
AU - Min, Sun Joon
AU - Lin-Jones, Jennifer
AU - Schapira, Matthieu
AU - Atadja, Peter
AU - Li, En
AU - Barsyte-Lovejoy, Dalia
AU - Arrowsmith, Cheryl H.
AU - Brown, Peter J.
AU - Liu, Feng
AU - Yu, Zhengtian
AU - Vedadi, Masoud
AU - Jin, Jian
N1 - Publisher Copyright:
© 2017 American Chemical Society.
PY - 2018/2/8
Y1 - 2018/2/8
N2 - PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is crucial for maturation of ribosomes and has been implicated in several diseases. We recently disclosed a highly potent, selective, and cell-active allosteric inhibitor of PRMT3, compound 4. Here, we report comprehensive structure-activity relationship studies that target the allosteric binding site of PRMT3. We conducted design, synthesis, and evaluation of novel compounds in biochemical, selectivity, and cellular assays that culminated in the discovery of 4 and other highly potent (IC 50 values: ∼10-36 nM), selective, and cell-active allosteric inhibitors of PRMT3 (compounds 29, 30, 36, and 37). In addition, we generated compounds that are very close analogs of these potent inhibitors but displayed drastically reduced potency as negative controls (compounds 49-51). These inhibitors and negative controls are valuable chemical tools for the biomedical community to further investigate biological functions and disease associations of PRMT3.
AB - PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is crucial for maturation of ribosomes and has been implicated in several diseases. We recently disclosed a highly potent, selective, and cell-active allosteric inhibitor of PRMT3, compound 4. Here, we report comprehensive structure-activity relationship studies that target the allosteric binding site of PRMT3. We conducted design, synthesis, and evaluation of novel compounds in biochemical, selectivity, and cellular assays that culminated in the discovery of 4 and other highly potent (IC 50 values: ∼10-36 nM), selective, and cell-active allosteric inhibitors of PRMT3 (compounds 29, 30, 36, and 37). In addition, we generated compounds that are very close analogs of these potent inhibitors but displayed drastically reduced potency as negative controls (compounds 49-51). These inhibitors and negative controls are valuable chemical tools for the biomedical community to further investigate biological functions and disease associations of PRMT3.
UR - https://www.scopus.com/pages/publications/85041911396
U2 - 10.1021/acs.jmedchem.7b01674
DO - 10.1021/acs.jmedchem.7b01674
M3 - Article
C2 - 29244490
AN - SCOPUS:85041911396
SN - 0022-2623
VL - 61
SP - 1204
EP - 1217
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 3
ER -